Cited by 481Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Open access

Wagle, Nikhil, Van Allen, Eliezer M., Treacy, Daniel J., Frederick, Dennie T., Cooper, Zachary A., Taylor-Weiner, Amaro, Rosenberg, Mara, Goetz, Eva M., Sullivan, Ryan J., Farlow, Deborah N., Friedrich, Dennis C., Anderka, Kristin, Perrin, Danielle, Johannessen, Cory M., McKenna, Aaron, Cibulskis, Kristian, Kryukov, Gregory, Hodis, Eran, Lawrence, Donald P., Fisher, Sheila, Getz, Gad, Gabriel, Stacey B., Carter, Scott L., Flaherty, Keith T., Wargo, Jennifer A., Garraway, Levi A.·2014·Cancer Discovery

DOI 10.1158/2159-8290.cd-13-0631PMC PMC3947296

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MAP–ERK kinase (MEK)1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with dabrafenib monotherapy. Mechanisms of clinical resistance to combined RAF/MEK inhibition are unknown. We performed whole-exome sequencing (WES) and whole-transcriptome sequencing (RNA-seq) on pretreatment and drug-resistant tumors from five patients with acquired resistance to dabrafenib/trametinib. In three of these patients, we identified additional mitogen-activated protein kinase (MAPK) pathway alterations in the resistant tumor that were not detected in the pretreatment tumor, including a novel activating mutation in MEK2 (MEK2Q60P). MEK2Q60P conferred resistance to combined RAF/MEK inhibition in vitro, but remained sensitive to inhibition of the downstream kinase extracellular signal–regulated kinase (ERK). The continued MAPK signaling-based resistance identified in these patients suggests that alternative dosing of current agents, more potent RAF/MEK inhibitors, and/or inhibition of the downstream kinase ERK may be needed for durable control of BRAF-mutant melanoma. Significance: This study represents an initial clinical genomic study of acquired resistance to combined RAF/MEK inhibition in BRAF-mutant melanoma, using WES and RNA-seq. The presence of diverse resistance mechanisms suggests that serial biopsies and genomic/molecular profiling at the time of resistance may ultimately improve the care of patients with resistant BRAF-mutant melanoma by specifying tailored targeted combinations to overcome specific resistance mechanisms. Cancer Discov; 4(1); 61–8. ©2013 AACR. See related commentary by Solit and Rosen, p. 27 This article is highlighted in the In This Issue feature, p. 1

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0631

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citation
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citation
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citation
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Self-citation
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citation
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citation
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Self-citation

Show all 27 references

Sorted by citations

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak‐Jones, C. L., Wolff, D. J., Younes, A., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,113
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,269
Self-citation
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 921
Self-citation
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Choi, Y., Schellens, J. H. M., Soria, J., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Urbanowitz, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 926
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 850
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C. Y., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 895
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kölch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 823
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Lim, Z.-F., & Ma, P. C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0818-2 · Cited by 664
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 618
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O. O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 553
Self-citation
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459
Targeting cancer with kinase inhibitors
Gross, S. D., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 459
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Sullivan, R. J., Infante, J. R., Jankú, F., Wong, D. J. L., Sosman, J. A., Keedy, V. L., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 446
Self-citation
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Tumour heterogeneity and the evolution of polyclonal drug resistance
Burrell, R. A., & Swanton, C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.005 · Cited by 435
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375
Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Islam, S. M. A., Díaz‐Gay, M., Wu, Y., Barnes, M. D., Vangara, R., Bergstrom, E. N., He, Y., Vella, M., Wang, J., Teague, J. W., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100179 · Cited by 364
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 351
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Wang, L., de Oliveira, R. L., Huijberts, S. C. F. A., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A. R., Song, J., Zevenhoven, J., Vries, G. T. L.-D., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.012 · Cited by 334
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 331
Self-citation
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Self-citation
Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., DAUD, A. I., Gonzalez, R. C., Sosman, J. A., Hamid, O., Schuchter, L. M., Cebon, J. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9345 · Cited by 290
Self-citation
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Yuan, Y., Allen, E. M. V., Omberg, L., Wagle, N., Amin‐Mansour, A., Sokolov, A., Byers, L. A., Xu, Y., Hess, K. R., Diao, L., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2940 · Cited by 280
Self-citation
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T. L., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 299
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 277
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R. A., Moldovan, C. S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 307
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Self-citation
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 264
Regulation of autophagy by canonical and non-canonical ER stress responses
Bhardwaj, M., Leli, N. M., Koumenis, C., & Amaravadi, R. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.007 · Cited by 250
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 252
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Germann, U. A., Furey, B. F., Markland, W., Hoover, R. R., Aronov, A. M., Roix, J. J., Hale, M. R., Boucher, D. M., Sorrell, D. A., Martínez-Botella, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0456 · Cited by 240
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 237
Self-citation
Toward precision medicine in glioblastoma: the promise and the challenges
Prados, M. D., Byron, S. A., Tran, N. L., Phillips, J. J., Molinaro, A. M., Ligon, K. L., Wen, P. Y., Kuhn, J. G., Mellinghoff, I. K., de Groot, J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov031 · Cited by 231
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
Hiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 233
Pathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J. C.-H., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 226
Self-citation
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 224
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF V600 -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L. M., Cebon, J. S., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 219
Self-citation
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
Hedberg, M. L., Goh, G., Chiosea, S. I., Bauman, J. E., Freilino, M. L., Zeng, Y., Wang, L., Diergaarde, B. B., Gooding, W. E., Lui, V. W. Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82066 · Cited by 208
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Meric‐Bernstam, F., Johnson, A. M., Holla, V. R., Bailey, A. M., Brusco, L., Chen, K., Routbort, M. J., Patel, K. P., Zeng, J., Kopetz, S., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv098 · Cited by 202
Review of Current Methods, Applications, and Data Management for the Bioinformatics Analysis of Whole Exome Sequencing
Bao, R., Huang, L., Andrade, J., Tan, W., Kibbe, W. A., Jiang, H., & Feng, G. (2014) · Cancer Informatics · doi:10.4137/cin.s13779 · Cited by 215
Delving deeper into resistance
Seton-Rogers, S. E. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3653 · Cited by 194
Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
MEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 198
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 184
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176
Current Advances in the Treatment of BRAF-Mutant Melanoma
Patel, H. M., Yacoub, N., Mishra, R., White, A., Yuan, L., Alanazi, S., & Garrett, J. T. (2020) · Cancers · doi:10.3390/cancers12020482 · Cited by 184
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Watson, I. R., Li, L., Cabeceiras, P. K., Mahdavi, M., Gutschner, T., Genovese, G., Wang, G., Fang, Z., Tepper, J. M., Stemke‐Hale, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1232-t · Cited by 173
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N. L., et al. (2017) · Nature · doi:10.1038/nature24040 · Cited by 168
Self-citation
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 172
Self-citation
Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance
Li, S., Song, Y., Quach, C., Guo, H., Jang, G.-B., Maazi, H., Zhao, S., Sands, N. A., Liu, Q., In, G. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09634-8 · Cited by 173
Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors
Brady, D. C., Crowe, M. S., Greenberg, D. N., & Counter, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1190 · Cited by 159
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance
Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
Gene expression based inference of cancer drug sensitivity
Chawla, S., Rockstroh, A., Lehman, M., Ratther, E., Jain, A., Anand, A., Gupta, A., Bhattacharya, N., Poonia, S., Rai, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33291-z · Cited by 150
Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts
Kemper, K., Krijgsman, O., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Song, J., Kuilman, T., Vis, D. J., Wessels, L. F. A., Voest, E. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404914 · Cited by 141
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 139
Participation of the Elderly Population in Clinical Trials: Barriers and Solutions
Denson, A. C., & Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100305 · Cited by 142
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 142
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang‐Gillam, A., & Cox, A. D. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 133
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 135
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 133
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Kwong, L. N., Boland, G. M., Frederick, D. T., Helms, T. L., Akid, A. T., Miller, J. P., Jiang, S., Cooper, Z. A., Song, X., Seth, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78954 · Cited by 120
Self-citation
ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicińska, E., Sulahian, R., Goodale, A. B., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 129
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
Lionarons, D. A., Hancock, D. C., Rana, S., East, P., Moore, C., Murillo, M. M., Carvalho, J., Spencer‐Dene, B., Herbert, E., Stamp, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.015 · Cited by 126
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 135
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, F., Ghiorzo, P., & Queirolo, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2602 · Cited by 128
Overcoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 131
EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Miao, B., Ji, Z., Tan, L., Taylor, M., Zhang, J., Choi, H. G., Frederick, D. T., Kumar, R., Wargo, J. A., Flaherty, K. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0295 · Cited by 124
Self-citation
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma
Roesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 123
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Goetz, E. M., Ghandi, M., Treacy, D. J., Wagle, N., & Garraway, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2073 · Cited by 123
Self-citation
Beyond BRAF: where next for melanoma therapy?
Fedorenko, I. V., Gibney, G. T., Sondak, V. K., & Smalley, K. S. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.476 · Cited by 117
ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Bhagwat, S. V., McMillen, W. T., Cai, S., Zhao, B., Whitesell, M., Shen, W., Kindler, L. J., Flack, R. S., Wu, W., Anderson, B. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0183 · Cited by 112
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
Gunda, V., Gigliotti, B. J., Ndishabandi, D., Ashry, T., McCarthy, M., Zhou, Z., Amin, S., Freeman, G. J., Alessandrini, A., & Parangi, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0296-2 · Cited by 111
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Hong, A., Moriceau, G., Sun, L., Lomeli, S. H., Piva, M., Damoiseaux, R. D., Holmen, S. L., Sharpless, N. E., Hugo, W., & Lo, R. S. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0682 · Cited by 109
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence
Singleton, K. R., Crawford, L. A., Tsui, E. L., Manchester, H. E., Maertens, O., Liu, X., Liberti, M. V., Magpusao, A. N., Stein, E. M., Tingley, J. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.022 · Cited by 102
Self-citation
A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*
Stuart, S. A., Houel, S., Lee, T., Wang, N., Old, W. M., & Ahn, N. G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047233 · Cited by 116
Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype
Paraiso, K. H. T., Thakur, M. D., Fang, B., Koomen, J. M., Smalley, I., John, J. K., Tsao, H., Flaherty, K. T., Sondak, V. K., Messina, J. L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0293 · Cited by 102
Self-citation
Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells
Korkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Sümer, S. O., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 99
Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
Faião‐Flores, F., Alves-Fernandes, D. K., Pennacchi, P. C., Sandri, S., Vicente, A. L. S. A., Scapulatempo‐Neto, C., Vazquez, V. D. L., Reis, R. M., Chauhan, J. S., Goding, C. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.348 · Cited by 101
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer
Facchinetti, F., Lacroix, L., Mezquita, L., Scoazec, J., Loriot, Y., Tselikas, L., Gazzah, A., Rouleau, É., Adam, J., Michiels, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.025 · Cited by 101
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes
Lee, L. H., Gasilina, A., Roychoudhury, J., Clark, J. P., McCormack, F. X., Pressey, J. G., Grimley, M. S., Lorsbach, R. B., Ali, S. M., Bailey, M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89473 · Cited by 98
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 94
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Ojha, R., Leli, N. M., Onorati, A., Piao, S., Verginadis, I. I., Tameire, F., Rebecca, V. W., Chude, C. I., Murugan, S., Fennelly, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0348 · Cited by 92
Self-citation
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Kefford, R. F., Howle, J. R., Saw, R. P. M., Thompson, J. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1688 · Cited by 96
Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
Smyth, T., Paraiso, K. H. T., Hearn, K., Rodríguez-López, A. M., Munck, J. M., Haarberg, H. E., Sondak, V. K., Thompson, N. T., Azab, M., Lyons, J. F., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0452 · Cited by 89
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells
Pal, H. C., Baxter, R. D., Hunt, K. M., Agarwal, J., Elmets, C. A., Athar, M., & Afaq, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5064 · Cited by 91

Authors: Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., Friedrich, D. C., Anderka, K., Perrin, D., Johannessen, C. M., McKenna, A., Cibulskis, K., Kryukov, G., Hodis, E., Lawrence, D. P., Fisher, S., Getz, G., Gabriel, S. B., Carter, S. L., Flaherty, K. T., Wargo, J. A., & Garraway, L. A.
Affiliations: Broad Institute (US)
Authors' Affiliations: 1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts
Corresponding author: Wargo, Jennifer A.
Garraway, Levi A.
ORCID: Wagle, Nikhil
Frederick, Dennie T.
Cooper, Zachary A.
Taylor-Weiner, Amaro
Rosenberg, Mara
Sullivan, Ryan J.
Johannessen, Cory M.
McKenna, Aaron
Cibulskis, Kristian
Kryukov, Gregory
Hodis, Eran
Lawrence, Donald P.
Getz, Gad
Gabriel, Stacey B.
Carter, Scott L.
Flaherty, Keith T.
Wargo, Jennifer A.
Garraway, Levi A.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2014-01-01
Volume: 4
Issue: 1
Pages: 61-68
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-13-0631
PMC: PMC3947296
OpenAlex: W2103557568
Cited by: 478
References: 27
Citations by year: 2026: 6 · 2025: 19 · 2024: 19 · 2023: 18 · 2022: 33 · 2021: 29 · 2020: 39 · 2019: 47 · 2018: 38 · 2017: 54 · 2016: 44 · 2015: 74 · 2014: 55
FWCI: 26.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (DP2OD002750)
National Human Genome Research Institute (U54HG003067)
National Cancer Institute (P50-CA-93683, R33CA155554, P01 CA163222 01A1, P50CA093683, T32CA009172, P30CA016672, P01CA163222)
National Institute of General Medical Sciences (T32GM007753)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: BRAF-mutant melanoma, acquired drug resistance, dabrafenib, trametinib, MEK2, MAPK pathway alterations, ERK inhibition, targeted therapy resistance, resistance mechanisms
MeSH terms: Aged, Antineoplastic Agents, Humans, Imidazoles, Male, Melanoma, Middle Aged, Mutation, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, raf Kinases, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks